You are here: Industry Insights > Liver cancer

News List

BDR Pharma launches generic version of Lenvatinib in India expresspharma
October 22, 2020
It is indicated for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer.
Roche gets positive CHMP opinion for Tecentriq plus Avastin to treat liver cancer expresspharma
September 21, 2020
The recommendation from the CHMP is based on results from the Phase III IMbrave150 study, which showed that Tecentriq in combination with Avastin reduced the risk of disease worsening or death.
US FDA declines to approve Merck and Eisai’s liver cancer combo therapy expresspharma
July 10, 2020
The FDA's complete response letter cited lack of sufficient evidence that the Keytruda-Lenvima combination therapy had a meaningful advantage over available treatments for the condition.
Roche's Tecentriq/Avastin combo wins US approval pharmatimes
June 04, 2020
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen cleared to treat unresectable or metastatic liver cancer.
Low-dose aspirin linked to reduced liver cancer risk worldpharmanews
March 13, 2020
Among adults at high risk of liver cancer, those who took low-dose aspirin were less likely to develop the disease or to die from liver-related causes.
Roche’s Ph III cancer immunotherapy trial reveals positive results for liver cancer biospectrumasia
December 18, 2019
The IMbrave150 study combination immunotherapy, with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab, has proven positive results by enhancing the potential of the immune system to combat Hepatocellular Carcinoma (HCC) among Asian pati
Researchers pinpoint cells, processes that lead to liver cancer biospectrumasia
September 24, 2019
Currently, there are few therapeutic options including surgery, but most HCC patients in the later stages of the disease, due to a lack of early diagnostic approaches, are ineligible for surgical treatment.
Lilly secures FDA approval for Cyramza to treat liver cancer pharmaceutical-technology
May 15, 2019
Eli Lilly has obtained US Food and Drug Administration (FDA) approval for the use of its Cyramza (ramucirumab injection, 10mg/ml solution) as a monotherapy to treat hepatocellular carcinoma (HCC).
Lucence Diagnostics to develop AI tools for treating liver cancer biospectrumasia
March 12, 2019
Lucence will be working with Olivier Gevaert, PhD, Assistant Professor of Medicine (Biomedical Informatics) and of Biomedical Data Science at the Stanford University School of Medicine.
Lucence Diagnostics to Develop AI Tools for Liver Cancer Treatment en-cphi.cn
March 12, 2019
Lucence Diagnostics, a genomic medicine company focused on personalizing cancer care, today announced a new project to develop AI algorithms for improving diagnosis and treatment of liver cancer.

Previous page 1 2 3 4 5 Next page